Home / Business and Economy / Merck Eyes $70B Revenue From New Drugs by Mid-2030s
Merck Eyes $70B Revenue From New Drugs by Mid-2030s
13 Jan
Summary
- Merck anticipates $70 billion in revenue from new growth drivers by the mid-2030s.
- Cardiometabolic and respiratory treatments revenue forecast increased to $20 billion.
- Infectious disease drug revenue projection significantly raised to $15 billion.
Merck is strategically accelerating its drug launch pipeline, forecasting substantial revenue growth from new business areas. By the mid-2030s, the company anticipates generating approximately $70 billion from these emerging drivers. This proactive approach is designed to counter the looming competitive pressures on its highly successful cancer treatment, Keytruda.
Specifically, Merck has revised its revenue projections upwards for key therapeutic categories. The outlook for cardiometabolic and respiratory treatments has been increased to an estimated $20 billion, up from a prior forecast of $15 billion. This adjustment highlights a strengthened belief in the market potential for these therapies.
Furthermore, the drugmaker has significantly enhanced its expectations for infectious disease drugs, now projecting them to contribute around $15 billion in revenue. This represents a considerable increase from the earlier estimate of $5 billion, indicating a robust pipeline and growing market confidence in Merck's advancements in combating infectious diseases.
